Bryan Johnson

Bryan Johnson (born 1977) is an American entrepreneur who made his fortune with the payments company Braintree, founded the brain-measurement company Kernel, and since 2021 has turned his own body into a heavily monitored anti-aging experiment called Blueprint, which he also sells as a consumer brand. Under the slogan "Don't Die" he has become the best-known practitioner of longevity Biohacking and grinders. Many aging researchers dispute his claims, chiefly because one uncontrolled subject following dozens of simultaneous interventions cannot show that any of them works.

§Overview

Johnson matters to this field less as a scientist than as a demonstration. Trained in business rather than biology, he publishes results as posts and videos, not papers. His project fuses three things normally kept apart: a single-subject experiment, a media persona with millions of followers, and a company selling products derived from the experiment. Critics argue that the third compromises the first; Johnson says he shares, and sells, his protocol so that others can learn from it and try parts if they choose.¹

§Career

§Payments and venture capital

Johnson grew up in a Mormon community in Utah, served a church mission in Ecuador, and studied at Brigham Young University and then at the University of Chicago's business school. In 2007 he founded Braintree, a payment processor. Braintree bought the peer-to-peer payments app Venmo in 2012, and in 2013 PayPal acquired the combined company for roughly $800 million; Time reported that Johnson walked away with more than $300 million. Within a year of the sale he ended his marriage and left the church.²

In 2014 he put $100 million into OS Fund, a venture fund for early-stage science and technology companies.² Its early portfolio, as reported by Fortune in 2014, included the lifespan company Human Longevity alongside asteroid-mining and drone ventures.

§Kernel

In October 2016 Johnson launched Kernel with $100 million of his own money, for "the sole purpose of building hardware and software to augment human intelligence". Its first planned product was a neuroprosthetic for cognitive deficits such as those of Alzheimer's disease and dementia, rooted in the Memory prosthesis research of its chief science officer, Theodore Berger.³ The New York Times later reported that Johnson had turned down a chance to start a similar company with Elon Musk, who went on to found Neuralink.⁴

The implant plan did not survive. Bloomberg Businessweek reported in 2021 that the body tends to degrade or reject implanted sensors and that brain surgery seemed unlikely to go mainstream, so Kernel had built two helmets that read the brain from outside the skull: Flow, which infers blood oxygenation changes by timing reflected laser pulses, and Flux, which uses small magnetometers to pick up the brain's magnetic fields. Each cost $50,000. The company had by then raised about $110 million, roughly half of it Johnson's.⁵ The helmets record brain activity for research; they are not a Brain–computer interface for controlling a device. Johnson stepped down from Kernel in 2023 and remains on its board.⁴

§Blueprint

§The regimen

Blueprint began in 2021.⁴ Bloomberg Businessweek reported in January 2023 that more than 30 doctors and health experts, led by the physician Oliver Zolman, were monitoring Johnson's bodily functions, that he was on track to spend at least $2 million on his body that year, and that his stated goal was for each organ to function like an 18-year-old's.⁶ The regimen combines a largely plant-based diet with calorie restriction, daily exercise, an 8:30 pm bedtime, dozens of Dietary supplements (Time counted 111 pills a day in 2023²) and frequent blood tests, scans and other biomarker measurements, many of which he publishes in an extreme form of the Quantified self approach. Johnson describes handing his life to an algorithm fed with his own data: "I eat what it says, I exercise the way it prescribes, I'll take whatever molecules it says."¹

§The company

Blueprint, run from Johnson's Los Angeles home, sells supplements, foods, blood-testing kits and other products tied to his regimen. In March 2025 The New York Times, citing people with knowledge of the business, reported 2024 revenue of about $40 million but losses of at least $1 million a month, with Johnson its sole investor.⁴ In November 2025 he announced a $60 million raise from investors including Kim Kardashian and Paris Hilton.¹ By 2026 he also ran a second longevity company, Immortals,⁷ launched in February 2026 as a programme offering a handful of clients his own protocol at a reported $1 million a year.

§Self-experiments

§Young plasma

Johnson underwent six monthly one-litre "young plasma exchanges" that ended in mid-2023. In one, plasma from his then-17-year-old son, Talmage,² was infused into Johnson, and Johnson's own plasma went to his 70-year-old father. In July 2023 he wrote that he had evaluated biomarkers from biofluids, devices and imaging with "no benefits detected", and stopped. The US Food and Drug Administration had warned in 2019 that infusing plasma from young donors has no proven clinical benefit, and the biochemist Charles Brenner called the practice "gross, evidence-free, and relatively dangerous".⁸ The idea draws on parabiosis experiments in mice, which have not translated into a demonstrated human benefit.

§Follistatin gene therapy

In September 2023 Johnson received a follistatin gene therapy from the startup Minicircle on the Honduran island of Roatán, outside US regulatory jurisdiction. It was not approved by the FDA, Minicircle had published no trial data, and the evidence that follistatin improves age-related muscle and bone loss came from mice. The company, which listed the treatment at $25,000, did not charge him. He reported a rise in blood follistatin levels, a sign that the gene was expressed rather than evidence of any health benefit. The physician and neuroscientist Christin Glorioso warned that such therapies "have no evidence for working" and could cause cancer or liver failure.⁹ Follistatin acts partly by blocking myostatin (see Myostatin inhibition and Gene therapy for aging).

§Rapamycin

On his company's blog, Johnson wrote that he stopped taking Rapamycin on 28 September 2024 after almost five years of testing different doses. He and his team concluded that "the benefits of lifelong dosing of Rapamycin do not justify the hefty side-effects", which he listed as intermittent skin and soft-tissue infections, lipid abnormalities, raised glucose and a higher resting heart rate.¹⁰ Like his other results, this is one person's experience and not a test of the drug.

§Pace-of-aging claims

Johnson's headline measures of success are DNA-methylation clocks, above all DunedinPACE, which estimates years of biological aging per calendar year. He co-created the Rejuvenation Olympics, a public leaderboard ranking entrants by a pace-of-aging blood test, and has been ranked first on it;¹ as of October 2026 the leaderboard listed him first with a DunedinPACE of 0.50. Entry requires a paid direct-to-consumer test. In the 2025 Netflix documentary about him he said his regimen had "reversed my biological age 5.1 years". The New York Times reported that internal tests between January 2022 and February 2024 showed his biological age by some measures rising by as much as 10 years; Johnson replied that the producers chose the 5.1-year figure and that "biological age measurements fluctuate".⁴

What one body can and cannot show

Every result Johnson reports comes from a single subject with no control, while dozens of interventions change at once and the measurements are selected and published by him or his company. Even a genuine slowdown on an epigenetic clock would not show which intervention caused it, or that it will translate into longer or healthier life: no aging clock is accepted by regulators as a surrogate for those outcomes. Blueprint sells products whose appeal rests partly on these numbers.

§Don't Die

"Don't Die" is Johnson's slogan and the name of the movement around him. In March 2025 he announced a religion named after it, which he said would save the human race.⁴ He calls it "the next major ideology for the human race", ties it to what he sees as the coming of superintelligence, and asks whether today's people are "the first generation who won't die", a claim close to Longevity escape velocity. He separates it from living forever, and from Mind uploading and Transhumanism: "I don't talk about mind-uploading. I don't talk about living in the cloud. I don't talk about transhumanism."¹ The Netflix documentary Don't Die: The Man Who Wants to Live Forever, directed by Chris Smith, was released on 1 January 2025.

§Reception

Many aging researchers have been openly critical. Speaking to Time in 2023, the USC gerontologist Pinchas Cohen said "Death is not optional; it's written into our genes"; Eric Verdin, chief executive of the Buck Institute for Research on Aging, called immortality "a pipe dream"; and Nir Barzilai said "What he's doing hasn't proven to be safe" and that Blueprint is "not an experiment that we accept as scientists or doctors".² By 2026 Time summarised the view of many longevity scientists as that Johnson peddles hype and unscientific advice and gives aging research a bad name.¹ Sympathetic figures in the longevity business credit him as a popularizer: Peter Diamandis told The New Yorker that "Bryan has done more to popularize longevity than any single person".

His business conduct has drawn separate criticism. The Times investigation in March 2025 reported that he required employees, partners and contractors to sign extensive confidentiality agreements, and that at least three former employees had filed complaints with the National Labor Relations Board calling the terms overbroad. It also reported that in a paid customer study of Blueprint's supplements and meals, with roughly 1,700 participants, internal documents recorded at least one side effect in about 60 percent; Johnson said these were "common side effects with any food, beverage or supplement". Zolman left Blueprint in 2024, reportedly after having concerns about some of its supplements. One of the NLRB complainants, his former fiancée and Kernel employee Taryn Southern, had sued him in 2021 over her firing; Johnson moved the case to arbitration, and in 2023 an arbitrator ruled that she must adhere to her employment separation agreement. Johnson disputes her account and has defended the agreements as setting clear boundaries.⁴

§Legacy

In mid-2026 Johnson, who has called himself "the healthiest person on the planet", announced that he had autoimmune gastritis, a condition in which the immune system attacks acid-producing cells of the stomach. He rejected the idea that his regimen caused it, linking it instead to a thyroid diagnosis at 21; a gastroenterologist told The New York Times that the disease has no known cause.⁷ The diagnosis neither validates nor refutes Blueprint; a single-subject regimen cannot answer that question in either direction.

Johnson is among the most prominent promoters of consumer Biological age testing, published biomarker panels and the slogan "Don't Die", and Blueprint and Immortals turn that attention into products. Whether any part of his regimen does what he says can be settled only by controlled trials in many people; the evidence published so far comes from his own measurements and an uncontrolled customer study.

§See also

• Blueprint protocol
• Biohacking and grinders
• Quantified self
• Epigenetic clocks
• Parabiosis and young blood
• Gene therapy for aging
• Kernel (neurotechnology company)
• Aubrey de Grey

§References

Footnotes

1. newsMosbergen, D. "Bryan Johnson Has Spent Millions Trying Not to Die. His Best Longevity Tip Is Free." Time, 5 January 2026.↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶Largely a question-and-answer interview, so most of it is Johnson describing his project in his own words.

2. newsAlter, C. "The Man Who Thinks He Can Live Forever." Time, 20 September 2023.↩ ↩² ↩³ ↩⁴ ↩⁵A magazine profile; besides his business history it carries the criticism of the regimen from Pinchas Cohen, Eric Verdin and Nir Barzilai.

3. newsMannes, J. "Bryan Johnson invests $100 million in Kernel to unlock the power of the human brain." TechCrunch, 20 October 2016.↩Reports the founding plan for a cognitive neuroprosthetic; Johnson himself estimated seven to ten years of work.

4. newsGrind, K. "How Bryan Johnson, Who Wants to Live Forever, Sought Control via Confidentiality Agreements." The New York Times, 21 March 2025.↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷Based on interviews with 30 people, internal documents and court records; Johnson declined many questions and disputed several findings.

5. news"Can a R1.5bn helmet unlock the secrets of the mind?" Bloomberg Businessweek, republished by Business Day, 22 June 2021.↩Read as republished, without a byline; the funding and price figures are given in dollars in the body text.

6. newsVance, A. "How to Be 18 Years Old Again for Only $2 Million a Year." Bloomberg Businessweek, 25 January 2023. ↩

7. newsHartocollis, A. "He said he was the world's healthiest man until a stunning diagnosis." The New York Times, August 2026, republished by the Honolulu Star-Advertiser, 23 August 2026. ↩ ↩²

8. newsMikhail, A. "Tech CEO Bryan Johnson admits he saw 'no benefits' after controversially injecting his son's plasma into his body to reverse his biological age." Fortune, 8 July 2023.↩Reports Johnson's own post ending the exchanges; the no-benefit finding is his self-assessment of his biomarkers, not a study.

9. newsRoyle, O. R. "Bryan Johnson is being used as a human guinea pig in unproven gene therapy injections worth $25,000 a pop in an island off Honduras." Fortune, 21 December 2023.↩His reported follistatin rise comes from his own posts and Bloomberg; Minicircle's own trial claims were unpublished.

10. statementJohnson, B. "I stopped taking rapamycin." Blueprint blog, 2024.↩Johnson's account of his own dosing and side effects, published on the store of the company that sells his protocol.